TY - JOUR
KW - Adolescent
KW - Adult
KW - Amphetamines/adverse effects/therapeutic use
KW - Cardiovascular Diseases/chemically induced/mortality
KW - Central Nervous System Stimulants/therapeutic use
KW - Cocaine/adverse effects
KW - Cocaine-Related Disorders/epidemiology/mortality/prevention & control
KW - Dopamine Uptake Inhibitors/adverse effects
KW - Female
KW - HIV Infections/chemically induced/mortality
KW - Hepatitis C/chemically induced/mortality
KW - Humans
KW - Incidence
KW - Male
KW - Mental Disorders/chemically induced/mortality
KW - Middle Aged
KW - Prevalence
KW - Virus Diseases/blood/chemically induced/mortality
KW - Young Adult
AU - M. Farrell
AU - N. K. Martin
AU - E. Stockings
AU - A. Bórquez
AU - J. A. Cepeda
AU - L. Degenhardt
AU - R. Ali
AU - L. T. Tran
AU - J. Rehm
AU - M. Torrens
AU - S. Shoptaw
AU - R. McKetin
A1 - 
AD - National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia. Electronic address: michael.farrell@unsw.edu.au.; Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Population Health Sciences, University of Bristol, Bristol, UK.; National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.; Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Department of Infectious Disease Epidemiology, Imperial College London, London, UK.; Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.; National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.; Discipline of Pharmacology, School of Medicine, University of Adelaide, Adelaide, SA, Australia.; National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.; Institute Mental Health Policy Research & Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Epidemiological Research Unit, Technische Universität Dresden, Klinische Psychologie & Psychotherapie, Dresden, Germany; Department of International Health Projects, Institute for Leadership and Health Management, IM Sechenov First Moscow State Medical University, Moscow, Russia.; Addiction Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain.; Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.; National Drug a(TRUNCATED)
BT - Lancet (London, England)
C5 - Opioids & Substance Use
CP - 10209
DO - 10.1016/S0140-6736(19)32230-5
IS - 10209
JF - Lancet (London, England)
LA - eng
M1 - Journal Article
PB - Elsevier Ltd
PY - 2019
SN - 1474-547X; 0140-6736; 0140-6736
SP - 1652
EP - 1667
EP - 
T1 - Responding to global stimulant use: challenges and opportunities
T2 - Lancet (London, England)
TI - Responding to global stimulant use: challenges and opportunities
U1 - Opioids & Substance Use
U2 - 31668409
U3 - 10.1016/S0140-6736(19)32230-5
VL - 394
VO - 1474-547X; 0140-6736; 0140-6736
Y1 - 2019
Y2 - Nov 2
ER -